



**Alex C. Spyropoulos, MD, FACP, FCCP, FRCPC**  
**Professor of Medicine**  
**The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell**  
**Professor – The Institute of Health System Science**  
**The Feinstein Institutes for Medical Research**  
**Professor – Elmezzi Graduate School of Molecular Medicine**  
**System Director – Anticoagulation and Clinical Thrombosis Services**  
**Northwell Health System**  
**New York, NY, USA**



Alex C. Spyropoulos, MD received his medical degree from the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, PA. He completed his internship and residency in internal medicine at the University of New Mexico Health Sciences Center in Albuquerque, NM. He is board certified in Internal Medicine.

Dr. Spyropoulos is a Professor of Medicine at the Zucker School of Medicine at Hofstra/Northwell and System Director of Anticoagulation and Clinical Thrombosis Services for the multi hospital Northwell Health System in NY. He is also a Professor of the Institute for Health Systems Science as part of the Feinstein Institutes for Medical Research and Professor of the Elmezzi Graduate School of Molecular Medicine. He is a Fellow of the American College of Physicians, American College of Chest Physicians, International Academy of Clinical and Applied Thrombosis/Haemostasis, and the Royal College of Physicians, Canada.

He has been involved as Principal Investigator, Scientific Committee member, Steering and Executive Committee member, or member of Data Safety Monitoring Board in multiple international, multicenter randomized trials – including registration trials - in thrombosis and anticoagulant therapy, including the BRIDGE trial, the MAGELLAN trial, the Kids DOTT trial, the PAUSE trial, the COVAC-TP trial, the PREVENT-HD trial, and the MICHELLE trial. He is Co-Principal Investigator of a multiyear R18 NIH/AHRQ grant on the creation and dissemination of an electronic-health record agnostic clinical decision support platform - Evidence Point and the developer and co-developer of the IMPROVE and IMPROVE-DD VTE risk assessment models in hospitalized medically ill patients, including COVID-19 patients He was the Chair or co-Chair of the Executive Committee for the global MARINER and HEP-COVID and IMPROVE-DD trials of medical and COVID-19 inpatients, as well as Principal Investigator of the CORE-19 registry of post-discharge outcomes in hospitalized COVID-19 patients, respectively. He is a founding member of ATLAS, a US-based ARO-CRO in thrombosis-related research.

He was a Steering Committee member for World Thrombosis Day as part of the International Society on Thrombosis and Haemostasis (ISTH), a Steering Committee member of the North American Thrombosis Forum, Chair of the 2020 Guidance Document on the Diagnosis, Prevention and Treatment of Venous Thromboembolism in Hospitalized Patients with COVID-19, Chair of the 2022 ISTH Antithrombotic Guidance Statements in COVID-19 inpatients, lead of the 2022 and updated 2024 ISTH Antithrombotic Guidelines in hospitalized non-critically ill

patients, and a member of the World Health Organization's Global COVID-19 Anticoagulation Collaborative Group. He is co-author of the 8<sup>th</sup>, 9<sup>th</sup> and co-Chair of the 10<sup>th</sup> 2022 American College of Chest Physicians Perioperative Guidelines on Antithrombotic Therapy, co-author of the 2008 and 2013, and co-Chair of the 2024 International Consensus Statement Guidelines on Prevention and Management of Venous Thromboembolism. He is a panel member of the 2020-2021 National Heart, Lung, and Blood Institute's Workshop on State of the Science Manifestations of Pulmonary Embolism.

He is on the editorial staff for Hospital Medicine and the Journal for Clinical Medicine, and former senior editor for Thrombosis and Haemostasis. He is a reviewer for many journals.

Dr. Spyropoulos' research studies, articles, letters, and editorials have been published in over 300 peer-reviewed journals including *The New England Journal of Medicine and NEJM Evidence, Blood, Blood Advances, Circulation, Lancet Hematology, Lancet, Annals of Internal Medicine, American Journal of Hematology, JAMA Internal Medicine, American Journal of Medicine, Journal of the American Heart Association, Chest, Thrombosis Haemostasis, American Journal of Cardiology, Journal of Thrombosis and Haemostasis, Journal of the American College of Cardiology, Clinical Applied Thrombosis and Haemostasis, and Thrombosis Research*. He also has edited multiple book chapters on the topic of antithrombotic therapy.